HPV Serum DNA Levels Predicting Outcome in p16+ Squamous Cell Head and Neck Cancer

Inclusion Criteria: * Histoloically proven primary cancer of the oropharynx, p16(+) and/or HPV (+), who are planned for treatment with resection, radiation and/or chemotherapy. * Subsites of oropharynx:include tonsil, base of tongue, vallecula, oropharyngeal wall, soft palate, glossotonsillar sulcus. * No or minimal smoking history (\</= 10 pack-year, no smoking in the past 12 months last 10 years based on documented history and/or subject report) * Age 18 years or older * Subjects are capable of giving informed consent or have an acceptabl;e surrogate capable of giving consent on the subjects behalf. * Enrollment on any other study, regardless of therapy is allowed. * Enrollment on any other tumor or tissue banking study is allowed. * Patients who have had blood drawn as part of another study, including the IRB-approved ENT Tumor Bank Study, may be included in this study even if the patient has already had surgery. Exclusion Criteria: * Previous chemotherapy or radiation therapy to the head and neck unrelated to current disease. * Previous surgery for head and neck cancer unrelated to current disease. * Widespread , biopsy-proven metastatic disease (stage IVC disease) at time of presentation (small indeterminate lung or mediastinal nodules are allowed) * Patients who have started induction chemotherapy prior to consideration for study eligibility. * Another active cancer except nonmelanomatous skin cancer. * History of cervical penile or anal cancer. * Patient treated with surgery, adjuvant radiation therapy or chemotherapy outside of the University of Pennsylvania. * History of smoking in the past last 12 months 10 years * History of 10 pack-years of cigarette smoking based on documented history and/or subject report * Presence of sidespread leukoplakia or erythroplakia.